vs
Side-by-side financial comparison of Axos Financial, Inc. (AX) and Bio-Techne (TECH). Click either name above to swap in a different company.
Axos Financial, Inc. is the larger business by last-quarter revenue ($392.2M vs $295.9M, roughly 1.3× Bio-Techne). Axos Financial, Inc. runs the higher net margin — 31.8% vs 12.8%, a 18.9% gap on every dollar of revenue. Over the past eight quarters, Axos Financial, Inc.'s revenue compounded faster (16.1% CAGR vs 4.2%).
Axos Financial is an American bank holding company based in Las Vegas, Nevada and is the parent of Axos Bank, a direct bank. It also offers registered investment adviser services and an electronic trading platform.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
AX vs TECH — Head-to-Head
Income Statement — Q3 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $392.2M | $295.9M |
| Net Profit | $124.7M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | — | 18.4% |
| Net Margin | 31.8% | 12.8% |
| Revenue YoY | — | -6.4% |
| Net Profit YoY | 18.5% | 68.3% |
| EPS (diluted) | $2.15 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $392.2M | — | ||
| Q4 25 | $385.1M | $295.9M | ||
| Q3 25 | $323.4M | — | ||
| Q2 25 | $321.4M | $317.0M | ||
| Q1 25 | $308.8M | $316.2M | ||
| Q4 24 | $307.9M | $297.0M | ||
| Q3 24 | $320.7M | $289.5M | ||
| Q2 24 | $290.9M | $306.1M |
| Q1 26 | $124.7M | — | ||
| Q4 25 | $128.4M | $38.0M | ||
| Q3 25 | $112.4M | — | ||
| Q2 25 | $110.7M | $-17.7M | ||
| Q1 25 | $105.2M | $22.6M | ||
| Q4 24 | $104.7M | $34.9M | ||
| Q3 24 | $112.3M | $33.6M | ||
| Q2 24 | $104.9M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | — | ||
| Q4 25 | 45.6% | 18.4% | ||
| Q3 25 | 46.3% | — | ||
| Q2 25 | 48.5% | -7.5% | ||
| Q1 25 | 47.9% | 12.2% | ||
| Q4 24 | 48.8% | 16.0% | ||
| Q3 24 | 49.6% | 13.8% | ||
| Q2 24 | 49.6% | 15.0% |
| Q1 26 | 31.8% | — | ||
| Q4 25 | 33.3% | 12.8% | ||
| Q3 25 | 34.7% | — | ||
| Q2 25 | 34.4% | -5.6% | ||
| Q1 25 | 34.1% | 7.1% | ||
| Q4 24 | 34.0% | 11.7% | ||
| Q3 24 | 35.0% | 11.6% | ||
| Q2 24 | 36.0% | 13.3% |
| Q1 26 | $2.15 | — | ||
| Q4 25 | $2.22 | $0.24 | ||
| Q3 25 | $1.94 | — | ||
| Q2 25 | $1.89 | $-0.11 | ||
| Q1 25 | $1.81 | $0.14 | ||
| Q4 24 | $1.80 | $0.22 | ||
| Q3 24 | $1.93 | $0.21 | ||
| Q2 24 | $1.75 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $3.1B | $2.0B |
| Total Assets | $29.2B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $172.9M | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $1.9B | $162.2M | ||
| Q1 25 | $2.0B | $140.7M | ||
| Q4 24 | $2.4B | $177.5M | ||
| Q3 24 | $2.6B | $187.5M | ||
| Q2 24 | $2.0B | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | $312.7M | $346.0M | ||
| Q1 25 | $377.4M | $330.0M | ||
| Q4 24 | $358.7M | $300.0M | ||
| Q3 24 | $313.5M | $300.0M | ||
| Q2 24 | $325.7M | $319.0M |
| Q1 26 | $3.1B | — | ||
| Q4 25 | $2.9B | $2.0B | ||
| Q3 25 | $2.8B | — | ||
| Q2 25 | $2.7B | $1.9B | ||
| Q1 25 | $2.6B | $2.0B | ||
| Q4 24 | $2.5B | $2.1B | ||
| Q3 24 | $2.4B | $2.1B | ||
| Q2 24 | $2.3B | $2.1B |
| Q1 26 | $29.2B | — | ||
| Q4 25 | $28.2B | $2.5B | ||
| Q3 25 | $27.4B | — | ||
| Q2 25 | $24.8B | $2.6B | ||
| Q1 25 | $24.0B | $2.6B | ||
| Q4 24 | $23.7B | $2.7B | ||
| Q3 24 | $23.6B | $2.7B | ||
| Q2 24 | $22.9B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.12× | 0.18× | ||
| Q1 25 | 0.14× | 0.16× | ||
| Q4 24 | 0.14× | 0.14× | ||
| Q3 24 | 0.13× | 0.14× | ||
| Q2 24 | 0.14× | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AX
| Net Interest Income | $306.3M | 78% |
| Noninterest Income | $86.0M | 22% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
